R&D Spending: Numbers for Pfizer, J&J, Merck, Lilly and Bristol
U.S. investment in R&D fell slightly this year, and is expected to start growing again next year, according to a new report out from the Batelle Memorial Institute, a nonprofit group that looks at that sort of thing.
A story in this morning’s WSJ has more on the issue; Health Blog readers may be particularly interested in some numbers from the report on R&D spending at big U.S. drug companies.
Of course, company-by-company figures like these don’t tell the whole story, in part because of the effects of consolidation. For example, Pfizer’s R&D spending may climb next year because of the Wyeth acquisition, but continuing cuts could mean the company’s R&D spending is lower than this year’s combined R&D spending for Pfizer and Wyeth.
Nevertheless, a numbers dump can still be interesting. Here it is:
R&D Spending, in millions of dollars
Company
Q1-Q3, ‘08
Q1-Q3, ‘09
Change
Pfizer
$5,642
$5,032
-10.8%
J&J
$5,469
$4,773
-12.7%
Merck
$3,419
$3,874
13.3%
Eli Lilly
$2,782
$3,110
11.8%
Bristol-Myers Squibb
$2,442
$2,590
6.1
Photo: Associated Press
Read more this great post here
